BNTC Stock — Benitec Biopharma Inc.: Cash, EV, Pipeline

Share price

$11.02

Market cap

$384.4M

Cash

$180.0M

Enterprise value

$204.4M

Balance sheet

Cash	$180.0M
Debt	$0.0M
Net cash	$180.0M
Enterprise value	$204.4M
Basic shares	34.4M shares
Fully diluted shares	61.3M shares
Fully diluted market cap	$675.7M
Cash per share	$5.23

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BNTC daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2030 - Jan 24, 2031	BB-301: Dose escalation phase 1b cohort 1	Phase 2	Oculopharyngeal Muscular Dystrophy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

BB-301

Phase 1 · Active Modality: DNA-directed RNA interference (ddRNAi) silence-and-replace gene therapy (AAV9)

Target PABPN1

Indications

Oculopharyngeal muscular dystrophy (OPMD)-derived dysphagia (Phase 1)

Status note Only clinical-stage therapeutic in development for OPMD dysphagia; Phase 1b/2a (NCT06185673) ongoing: all 6 Cohort 1 subjects completed 12-month follow-up, first two Cohort 2 subjects treated, no treatment-related SAEs. Single intramuscular administration to pharyngeal muscles. Orphan Drug Designation (EU and US) plus Fast Track (US). No dated readout guidance in this filing.

Per-asset detail extracted from the 10-Q filed 2026-05-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	BB-301: Dose escalation phase 1b cohort 1
Lead indication	Oculopharyngeal Muscular Dystrophy
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06185673	Phase 2	Recruiting	Sponsor	BNTC	—	Oculopharyngeal Muscular Dystrophy	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Benitec Biopharma, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	40,000	+22,500	0.03%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

BNTC — Benitec Biopharma Inc.